The value of clinical trials in Denmark

The public-private NEXT Partnership is working to make Denmark the pharmaceutical industry’s first choice for clinical trials. Clinical trials are conducted to ensure the safety and efficacy of new pharmaceutical products before they can be approved by regulatory authorities.

In order to shed light on the benefits of conducting clinical trials, NEXT Partnership, The Danish Association of the Pharmaceutical Industry and Invest in Denmark asked Copenhagen Economics to quantify the value generated by clinical trials in Denmark.

The main conclusions of the study are:

• Clinical trials by pharmaceutical companies deliver value to the Danish society. On average, a clinical trial improves GDP by DKK 0.9m and the public budget by DKK 1.2m.
• The positive economic effects arise from trials conducted in Denmark through several drivers; by contributing to more and better healthcare, by creating highly productive jobs and by propelling new research in Life Sciences. 

The study is commissioned by NEXT Partnership, The Danish Association of the Pharmaceutical Industry and Invest in Denmark.

Download executive summary in English